Drug Test Anal. 2019 Jan 30. doi: 10.1002/dta.2572.
[Epub ahead of print]
Kraemer M1, Broecker S2, Madea B1, Hess C1,3.
Cannabidiol (CBD) is a non-psychoactive cannabinoid, which is of growing medical interest. Previous studies on the metabolism of CBD showed mainly the formation of hydroxylated or oxidized derivatives, of carboxylic acids or modifications of the aliphatic side chain. Using incubation of CBD with hepatic microsomes of mice, the formation of carbon monoxide was reported. We investigated the phase I metabolism of CBD and cannabidivarin (CBDV) using in vitro experiments with human liver microsomes in order to discover so far not considered metabolites. Identification of metabolites was done by liquid chromatography coupled with quadrupole time of flight mass spectrometry (LC-QToF-MS). Within these experiments, we came across decarbonylation of CBD and CBDV. Further investigations were focused on observed decarbonylated CBD (DCBD). To confirm this metabolite in humans in vivo, plasma samples containing large amounts of cannabinoids as well as serum and urine samples, collected after a voluntary intake of a CBD containing food supplement, were analyzed by LC coupled to triple quadrupole mass spectrometry (LC-QQQ-MS). DCBD was detected in in vitro incubation mixtures, serum samples and urine samples (after alkaline or enzymatic hydrolysis) collected after the voluntary intake, as well as in plasma samples of cannabis users. DCBD appears to be an important supplementary human metabolite that might be helpful for the analytical confirmation of a CBD uptake and might improve the interpretation of the consumption of CBD containing products. Results of this study indicate a prolonged detectability of DCBD in comparison to CBD after oral CBD ingestion.
This article is protected by copyright. All rights reserved.
LC-QQQ-MS; LC-QTOF-MS; cannabidiol; decarbonylation; metabolism
- PMID: 30698361
- DOI: 10.1002/dta.2572